121 results about "Hepatocellular Cancers" patented technology

A cDNA molecule corresponding to a newly discovered human gene is disclosed. The new gene, which is frequently deleted in liver cancer cells and cell lines, is called the DLC-1 gene. Because the gene is frequently deleted in liver cancer cells, but present in normal cells, it is thought to act as a tumor suppressor. This gene is also frequently deleted in breast and colon cancers, and its expression is decreased or undetectable in many prostate and colon cancers. Also disclosed is the amino acid sequence of the protein encoded by the DLC-1 gene. Methods of using these biological materials in the diagnosis and treatment of hepatocellular cancer, breast cancer, colon cancer, prostate cancer, and adenocarcinomas are presented.

The invention features a method for determining methyl transferase activity of a polypeptide and screening for modulators of methyl transferase activity. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer or hepatocellular carcinoma using the modulator.

The invention relates to a human asialoglycoprotein receptor (ASGPR) monoclonal antibody as well as a preparation method and application thereof. The monoclonal antibody can be used for well recognizing an ASGPR antigen, cannot perform cross reaction with other proteins, and is very high in specificity and sensitivity. The antibody disclosed by the invention can be applied to identification of primary hepatocellular carcinoma and metastatic liver cancer, separation and detection of circulating liver cancer cells, liver imaging and targeted delivery of liver medicines or genes.

This invention provides methods for detecting serum GEP level. This invention further provides methods for determining whether a subject is afflicted with Hepatocellular carcinoma (HCC) by measuring serum GEP level. In another embodiment, this invention provides methods for the suppression of HCC growth and progression both in vitro and in vivo by treating a patient with anti-GEP monoclonal antibody A23.

Methods are provided for detecting a cell proliferative disorder associated with TSLC1 by contacting a proliferating cell of a subject suspected of having the disorder with a reagent that detects TSLC1 and detecting the level of TSLC1 in the proliferating cell. TSLC1 is a single gene whose expression is reduced or absent in A549 and some other NSCLC, hepatocellular carcinoma and pancreatic cancer cell lines. It has further been discovered that TSLC1 expression or suppression is perfectly correlated with promoter methylation state. Restoration of TSLC1 expression to normal or higher levels is sufficient by itself to suppress tumor formation. The invention further provides methods of treating such disorders by contacting cells of a patient suffering from the disorder with a therapeutically effective amount of a reagent that modulates TSLC1 level in the proliferating cells.

The present invention addresses the problem of providing a hepatocellular carcinoma marker which can be used for detecting the presence of hepatocellular carcinoma and comprises a glycoprotein that can occur in the liver only when the carcinoma is developed regardless of the change in the condition of the liver. The present invention provides a hepatocellular carcinoma marker which comprises an NPA lectin-binding glycoprotein containing an NPA lectin-binding sugar chain epitope having at least one property selected from the following properties (1) to (5) (1) the sugar chain epitope does not contain core fucose (a fucose alpha 1(arrow) 6 sugar chain); (2) the sugar chain epitope contains a composite sugar chain that contains three (less than four) mannose molecules; (3) the sugar chain epitope does not contain a high-mannose-type sugar chain containing five or more mannose molecules; (4) the sugar chain epitope comprises a composite sugar chain that does not rely on the bindability to LCA lectin; and (5) the sugar chain epitope comprises a composite sugar chain that does not rely on the bindability to ConA lectin. The presence of the development of hepatocellular carcinoma or the degree of the progression or malignancy of the carcinoma can be determined by detecting the hepatocellular carcinoma marker of the present invention in a sample of interest.

It is disclosed herein that miR-221 and miR-222 down-regulate PTEN and TIMP3 tumor suppressors, resulting in TRAIL resistance. The present invention provides research, diagnostic, and therapeutic tools and methods related to this discovery. Diagnostics, prognostics and treatments for human hepatocellular cancer and non-small cell lung carcinoma having a TRAIL resistance are particularly described herein.

The invention discloses a monoclonal antibody or sections thereof, which is sieved by utilizing a bacteriophage antibody database technology and prepared by utilizing a gene engineering method, of VEGFR2, and also discloses a carrier containing polynucleotide, which codes the monoclonal antibody or sections thereof, host cells, a method of preparing and purifying, and applications. The monoclonal antibody or sections thereof is used for preparing medicines for curing diseases caused by cancer new-born blood vessels. The diseases contain but not limited to following cancers: non-small cell lung cancer, metastatic non-small-cell lung cancer, hepatocellular carcinoma, metastatic hepatocellular carcinoma, HER2 negative metastatic breast cancer, metastatic gastric gland cancer, metastatic colorectal cancer, metastatic melanoma, and metastatic renal cell carcinoma.

The present invention discloses a new specific antibody (humanized monoclonal antibody huSM5-1 and human-mouse chimeric antibody SM5-1) specific for melanoma, breast cancer and hepatocellular carcinoma, and its related antigen encodes the Isolated nucleic acid molecules of antibodies, and methods of making said antibodies. The present invention also relates to the application of the antibody and / or isolated nucleic acid molecule in the preparation of medicaments for diagnosing and treating malignant tumors.

The invention discloses methylated sites of liver-cancer-related human genes NUDT2 and PCDH8 and applications of the methylated sites of the human genes NUDT2 and PCDH8. According to the methylated sites and the applications, a pyrosequencing method is adopted for quantitatively detecting the methylation level of the specific site cg04322134 of the NUDT2 gene and the site cg20366906 of the PCDH8 gene, a unique primer is designed aiming at each site, and the primers comprise upstream and downstream PCR amplification primers and a pyrosequencing primer, wherein one of the amplification primers is provided with a biotin label. The rapid and accurate quantitative detection can be carried out on the methylation level of the specific sites of the genes NUDT2 and PCDH8, and the result shows that the methylation level of the two sites has obvious change in primary hepatocellular carcinoma patients.

Disclosed herein is a method for determining the prognosis of a subject diagnosed with hepatocellular carcinoma based on the expression level of at least one microRNA in the non-cancerous liver tissue of the subject. According to various embodiments of the present disclosure, expression levels of miR-486-3p, miR-876-5p, and miR-381 are positively associated with a favorable prognosis, while expression levels of miR-30c, miR-432, and miR-15b are negatively associated with a favorable prognosis.